SCHEMBL4866066

SCHEMBL4866066

Cc1ccc(Cc2cc3c(c(C(=O)O)c2)OC(c2ccccc2)(c2ccccc2)O3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.41
PTPN1 P18031 5/20 0.39
PTPN2 P17706 2/20 0.39
PTPN6 P29350 2/20 0.39
SRD5A2 P31213 1/20 0.39
CNR1 P21554 5/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HMGB1 P09429 1/20 0.37
CXCL12 P48061 1/20 0.37
AKR1C3 P42330 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
KLKB1 P03952 1/20 0.35
CTSB P07858 1/20 0.35
MMP9 P14780 1/20 0.35
DNMT1 P26358 1/20 0.35
DNMT3B Q9UBC3 1/20 0.35
DNMT3L Q9UJW3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871124 0.89 KDM4E (0.40) SRD5A2CNR1ALDH1A1KDM4EGAA
SCHEMBL8285530 0.82 CNR1 (0.44) SRD5A2CNR1ALDH1A1KDM4EAKR1C3
SCHEMBL4868360 0.74 CNR1 (0.45) CNR1ALDH1A1KDM4EHSD17B10AKR1C3
SCHEMBL4863705 0.74 CNR1 (0.39) CNR1
SCHEMBL4863795 0.72 CNR1 (0.40) SRD5A2CNR1ALDH1A1GAASMN1; SMN2
SCHEMBL4866967 0.71 CNR1 (0.45) CNR1
SCHEMBL4867176 0.71 NR4A2 (0.41) CNR1ALDH1A1KDM4EGAAHSD17B10
SCHEMBL9040225 0.70 CNR1 (0.42) SRD5A2CNR1ALDH1A1
SCHEMBL6226020 0.69 CNR1 (0.64) SRD5A2CNR1ALDH1A1AKR1C3
SCHEMBL4863679 0.69 CNR1 (0.42) HNF4APTPN1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 HNF4A 2318/4885PTPN1 2629/4885PTPN2 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.